SINCE the introduction of thiopentone as an intravenous anaesthetic in 1934, it has been realised that the drug is not completely satisfactory for all types of patients and different durations of surgery. Certain difficulties have been overcome by the realization that by using smaller doses the toxicity is reduced to a minimum. However, the fact remains that while anaesthesia is short, recovery results because the drug is stored away in muscle to be released slowly over many hours. This makes it unsatisfactory for outpatients and even patients in hospital often remain drowsy for long periods after the operation unless therei is pain or discomfort.
Search for a shorter acting drug led to the synthesis of methohexitone (Brietal) and in many ways it is ideal for outpatients, both dental and those for minor surgery. However even this drug is not rapidly broken but stored up in the body to some extent, and there is cumulation on repeated dosage (Clarke and Dundee, 1966) . It has also the drawback that excitatory effects (twiching, hiccough, etc.) occur, though their incidence can be reduced by slow injection and opiate premedication (Dundee et al, 1961) .
Of the non-barbiturates tested, propanidid is the first short-acting drug to pass the rigorous clinical trials. It has been shown to produce few excitatory effects, little hypotension, and recovery is as rapid as one could want (Dundee and Clarke, 1964) . It is sufficiently insoluble in water to necessitate the use of a "solubilizing agent", and is available as a 5 per cent solution, which remains stable for over two years. Its value is marred by the viscosity of the solution, the prolongation of the action of suxamethonium and a higher incidence of postoperative sickness than follows the use of barbiturates. In order to assess the usefulness of the drug and the general validity of the above conclusions it was decided to carry out a group trial.
ORGANISATION OF THE TRIAL For this study a number of practising anaesthetists of varying seniority and experience were asked to participate. Each was given a minimum of 20 halfgramme ampoules of the drug and a brief factual summary of its pharmacology. They were asked to use it in their routine practise in place of thiopentone or methohexitone. On completion of the study each was asked to fill in a questionnaire comparing propanidid with the barbiturates. Completed questionnaires, often with detailed reports, were received from 66 anaesthetists, covering 1402 anaesthetics for a wide variety of surgery (Table I) . 
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1121 The participants were asked to express a preference with regard to various properties and actions, also whether they thought the drug was likely to be of clinical use. If the answer to the latter question was "yes", they were to suggest likely fields of usefulness. Finally, they were asked about difficulties encountered, particularly those met in certain techniques or types of procedures.
RESULTS
The results from the specific questions (Table II) indicate that in the dosage used (4-6 mg/kg was recommended) propanidid was preferred with regard to cardiovascular and respiratory depression by most people. Recovery was almost universally found to be more rapid after propanidid. On the other hand it was not popular because of its physical properties. The opinions about vomiting were more equivocal, because the majority of participants found no difference in its incidence but of those who did, most people found that thiopentone was less emetic. The overall opinion of the drug was that it was likely to have a place in clinical use. Of the 48 taking this view 45 mentioned out-patients specifically, 25 mentioned minor in-patients and 4 suggested its use for "poor risk" patients.
The objections to the drug though expressed in many different ways can be classified as in Table III . The largest group encountered was due to its viscosity, which made injection difficult. As one would expect from a short acting drug, there was difficulty in attaining smooth surgical anaesthesia because of the slow uptake of the volatile supplement. Other less common objections are also given in the table. Objections to the viscosity, "oiliness" or to the necessity for using a l a r g e n e e d l e 
DISCUSSION
The method of group trial gives an opportunity of finding out early in the life of a drug whether anaesthetists would really want to use it. The answers to the specific questions must be judged in the light of the information already supplied to the anaesthetists, which may have influenced some of them. There was a high incidence of "no preference" answers to three of the questions. Where there was a definite comment about the rapid recovery, the participant was not asked whether this was a good thing for the patient and some expressed views to the contrary, except for out-patients. The rapidity of recovery led to the difficulty in take over of an inhalation agent (Table III) but this can be overcome with practise.
The physical properties of the agent were mentioned frequently in the general reports of difficulties encountered. The oiliness, tendency to form bubbles and necessity for use of a large needle were all unpopular. The latter is a particular difficulty with children but can be overcome by diluting the drug from a 5 per cent to a 3.5 per cent solution. A less viscous preparation is on trial at present and seems very similar in its other properties to the older solution, except that it can be injected through a 23 s.w.g. (No. 12) needle with acceptable speed. Against these objections, a drug in solution has advantages over the barbiturates, which are only stable in powder form.
The high incidence of postoperative vomiting after propanidid has been noted by Dundee, Kirwan and Clarke (1965) and by Goldman and Kennedy (1964) but many general surveys of its use have not mentioned this complication (Howells et al, 1964; Swerdlow, 1965; Gunner et al, 1965) . Certainly the majority of the sickness is in the first hour after the drug and if atropine premedication alone is used, there is little late nausea or vomiting.
The difficulties mentioned spontaneously included prolongation of the action of suxamethonium. For most work this action presents no problems but during bronchoscopy and electro-convulsive therapy, where nitrous oxide is not normally used, the patient may regain consciousness before the relaxant has worn off. This is particularly unfortunate in E.C.T. where the other properties of the drug would have made it very useful.
A high incidence of spontaneous muscle movements have not been encountered by the authors using optimal dosage (4-6 mg/kg) but higher doses or very rapid injection, increase the incidence of these complications. Certainly the use of large doses is no substitute for a technique of rapid administration of inhalation agents after intravenous induction. Some anaesthetists also found hypotension common after the use of large doses and in ill patients. With such it is particularly essential to have a smooth "take over" after the induction and the injection of tubocurarine immediately before the propanidid in major surgery does achieve this result. In low dosage the drug has less cardiovascular toxicity than thiopentone and could be used for poor-risk cases though it is doubtful whether this is a specific indication.
Many of the anaesthetists who suggested using the drug for outpatients had not themselves used it for this purpose but all of those who had (25) were satisfied with its action. As sole agent for the extraction of 1-2 teeth and for the rapid incision of an abscess the drug is ideal and as main agent for slightly larger procedures it is satisfactory. Another field where the rapid recovery is most valuable is in the electrical conversion of cardiac arrythmias where even if a second shock is necessary the duration of sleep just matches the duration of the procedure. No premedication is necessary and in this field as with most outpatients where the drug was used vomiting has been very rare. SUMMARY A group trial of the new intravenous anaesthetic, propanidid, is described in which 66 anaesthetists took part. The main difficulties encountered with the preparation were its high viscosity, its brief action and, less consistently, early postoperative vomiting. Now that a less viscous preparation is available it would appear that the drug has a definite place for outpatient and brief in-patient anaesthesia. ADDENDUM Since this study was completed the less viscous form of propanidid has been marketed in the name of Epontol. The lesser viscosity probably affects the clinical acceptability of the drug.
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